Eudaimonia Partners’s Guardant Health GH Stock Holding History

Eudaimonia Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-168	Closed	-$26K	–	749
2021 Q1	$26K	Hold	168	–	–	0.01%	859
2020 Q4	$22K	Buy	+168	New	+$19.3K	﹤0.01%	839

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Eudaimonia Partners's GH Position: Q2 2021 in Review

Eudaimonia Partners sold out of Guardant Health (GH) in Q2 2021, closing a stake of 168 shares — an estimated $26K sold.

Eudaimonia Partners first reported a position in GH in Q4 2020 and held it in 2 quarters. The position peaked at $26K in Q1 2021. 417 funds tracked by Wall St. Rank hold GH as of Q2 2021.

Eudaimonia Partners reported no remaining Guardant Health position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 168 Guardant Health shares in Q2 2021, an estimated $26K.
Eudaimonia Partners first reported a position in Guardant Health in Q4 2020 and held it in 2 quarters.
Eudaimonia Partners's Guardant Health position peaked at $26K in Q1 2021.
417 funds tracked by Wall St. Rank held Guardant Health as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.